US FDA Commissioner Scott Gottlieb chose to focus on antimicrobial reimbursement ideas rather than development policy in his announcement of new draft guidance on the Limited Population Antibacterial Drug (LPAD) pathway that was issued June 12.
LPAD is designed to speed approvals of novel antibiotics for small populations with serious or life-threatening conditions. (See sidebar.)







